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Purpose: In the critically ill, sarcopenia is associated with a variety of adverse outcomes however there is no 
consensus regarding its management. This study aimed to systematically review the evidence for 
interventions for the management and prevention of sarcopenia in critically ill patients.  
Materials and Methods: Bibliographic databases were searched according to pre-specified criteria 
(PROSPERO-CRD42018086271). Randomised controlled trials (RCTs) investigating interventions to 
preserve muscle mass and/or function in critically ill patients were included. Two independent authors 
selected the articles and assessed bias using the Cochrane Risk of Bias Tool.  
Results: Twenty-two eligible RCTs were identified comprising 2792 patients. Three main groups of 
interventions were implemented in these trials: neuromuscular electrical stimulation (NMES), exercise-based 
and nutritional. Both the interventions and outcomes measured varied significantly between studies . NMES 
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was most frequently studied as an intervention to preserve muscle mass whilst exercise-based treatments 
were evaluated as interventions to preserve muscle function. There was significant variation in the efficacy of 
the interventions on sarcopenia markers and secondary outcomes.  
Conclusions: NMES and exercise-based interventions may preserve muscle mass and function in patients 
with critical illness. There is a lack of consistency seen in the effects of these interventions. Further, large, 
high quality RCTs are required.  
 
Keywords: sarcopenia; muscle wasting; critical illness; intensive care; intensive care unit acquired 
weakness; ICU-AW. 
 
 
Introduction: 
Sarcopenia is defined as a decline in skeletal muscle mass and function [1]. Sarcopenia can be further 
classified as primary, age-related sarcopenia and secondary sarcopenia which is associated with a variety of 
risk factors including malnutrition, immobilisation, disease and inflammation [2,3]. Sarcopenia primarily 
results from the deterioration of fast twitch type II muscle fibres which are crucial to muscle strength and 
performance [4]. Observational studies have reported a high prevalence of sarcopenia in hospitalised 
patients and in as many as 60% of patients admitted to critical care for mechanical ventilation [5-7]. Crucially, 
patients with sarcopenia have been shown to be at increased risk of mortality, longer hospital stay and a 
greater readmission rate [7-13]. Mechanically ventilated, critically ill patients with low skeletal muscle-area 
have been shown to have a 25% increased risk of in-hospital mortality compared to patients with normal 
skeletal muscle area [7].  Furthermore, sarcopenia has been shown to result in significant morbidity including 
a loss of functional independence in patients surviving to hospital discharge [8]. 
 
Currently, there is no gold standard for the assessment of patients at risk of sarcopenia in critical care. 
Computed tomography (CT) and magnetic resonance imaging (MRI) are often used to assess muscle mass 
however these techniques are expensive and cannot be performed at the bedside [14,15]. Hand grip 
strength (HGS) is frequently used to assess muscle function and is strongly correlated with other measures 
of strength [16].  Other metrics include the 6-minute walk test (6MWT) and Medical Research Council (MRC) 
muscle scale [17]. Several interventions have been investigated to manage sarcopenia. Exercise-based 
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interventions such as early mobilisation have been shown to help prevent muscle wasting in addition to 
having a positive impact on mood, quality of life and mobility in patients recovering from critical illness [18]. 
For patients unable to engage in exercise-based interventions, neuromuscular electrical stimulation (NMES) 
has emerged as an alternative treatment [19].  
 
Despite the adverse outcomes experienced by critically ill patients with sarcopenia, there is no consensus 
regarding its management. This study aimed to systematically review the evidence for the management and 
prevention of sarcopenia in critically ill patients, with a view to describing those that are clinically effective.  
Through this process we aim to suggest further work that may be required prior to introduction of therapies 
targeting sarcopenia in routine clinical practice in patients with critical illness. 
 
Materials and Methods: 
Standard systematic review methodology was performed according to a pre-specified study protocol 
(PROSPERO-CRD42018086271). Searches were carried out using the Medline/PubMed and Embase 
bibliographic databases. In addition, the Cochrane Database of Systematic Reviews and PROSPERO were 
checked to avoid redundant repetition of review and trials registers searched to identify ongoing studies. 
 
Search strategy 
Our search strategy focussed on two keywords: sarcopenia and critical illness. Search terms were 
extrapolated from the keywords and MeSH headings were included to ensure that no papers using non-
standard terms were missed (see supplement 1 for full search strategy). Intensive care unit-acquired 
weakness (ICU-AW) was a term that appeared frequently during background reading. ICU-AW shares many 
similarities with sarcopenia and as such we decided to include it in our search terms to ensure that papers 
relevant to sarcopenia were not missed. Searches were limited to English language articles. 
 
Study selection  
The population of interest was patients with critical illness. We defined this as patients who were admitted to 
a high dependency unit (HDU) or intensive care unit (ICU) for level 2 or level 3 care.  Only randomised 
controlled trials evaluating an intervention that aimed to treat sarcopenia by improving or maintaining muscle 
mass/size and/or muscle function (strength or performance) were included. The comparator of interest was 
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usual care or placebo/sham intervention. Primary outcomes of interest included any measure of muscle 
mass/size and muscle function. Secondary outcomes included length of ICU/hospital stay, days 
mechanically ventilated, rate of hospital readmission or mortality. Studies were checked for duplication 
between databases. Following this, titles and abstracts were screened against the inclusion and exclusion 
criteria by two reviewers (NB and SPT). Any disparities were discussed and if required, referred onto a third 
reviewer for final decision. Following initial screening, full papers were obtained and examined to ensure 
eligibility for data extraction.  
 
Data extraction, risk of bias assessment and evidence synthesis 
A data extraction form, modelled on the Cochrane data extraction pro-forma, was used. Data was extracted 
by one reviewer and checked by another. All studies that met the inclusion criteria were assessed using the 
Cochrane risk of bias tool. This assessed six areas: random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and 
selective outcome reporting. Each of these areas was classified as high risk, low risk or unclear risk of bias. 
Narrative synthesis of evidence was undertaken for all included studies. Meta-analysis was not possible due 
to heterogeneity of study design and outcomes. 
 
 
Results: 
The PRISMA flow diagram in Figure 1 illustrates the process of article selection. Searches of the 
PubMed/Medline and Embase databases resulted in 204 and 116 papers being returned respectively . Forty-
eight duplicates were found between databases leaving 272 unique papers. An additional 4 papers were 
identified from reference lists. Following title/abstract screening 37 papers underwent full review. Fifteen 
papers did not meet inclusion criteria leaving 22 full papers included for evidence synthesis. Characteristics 
of included studies are summarised in Table 1. In total, the 22 studies comprised 2792 patients. Study size 
varied from 8 patients to 1372 patients, with recruitment occurring primarily within the first 24-48 hours of 
ICU admission. Eighteen studies described the severity of critical illness using established scores such as 
Sequential Organ Failure Assessment (SOFA) and Acute Physiology And Chronic Health Evaluation II 
(APACHE II).  
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Interventions 
NMES was evaluated in 11 studies [20-30]. There was wide variation in protocols for NMES administration, 
summarised in Table 1. Exercise-based interventions were evaluated in 11 studies [25,26,30-38]. Exercise-
based interventions encompassed a variety of different techniques with significant heterogeneity of 
intervention protocols. Nutrition-based therapy by means of early enteral or parenteral feeding was evaluated 
in 3 studies and essential amino acid supplementation was evaluated in 1 study [35,39-41]. For the purposes 
of this review, we categorised interventions into 4 groups: NMES, exercise-based, nutritional and combined 
interventions. 
 
Comparators 
The comparator in most studies was ‘usual care’ (n=17), the remainder utilised a placebo/sham intervention 
(n=5). In studies of NMES, the use of sham intervention occurred whereby electrodes were attached, but no 
current was passed through the target muscle. Several studies of NMES used a patient’s contralateral limb 
as a paired control by only stimulating one quadriceps (n=4). Placebo/sham did not occur with the exercise-
based interventions, as this was not feasible.  
 
 
 
Outcomes 
Only 4 studies measured both components of sarcopenia – muscle mass/size and muscle function. The 
remainder of studies measured either muscle mass/size or muscle function. Muscle function alone was 
assessed in 12 studies and muscle mass/size alone was assessed in 6 studies. Table 2 summarises the 
different sarcopenia related outcomes used in these studies. A variety of additional clinical outcomes were 
reported including: in-hospital mortality, number of days mechanically ventilated, length of ICU/hospital stay, 
readmission rate and post-discharge mortality.  
 
Risk of Bias 
An overview of the risk of bias assessment is presented in Table 2. Some studies were well conducted using 
large cohorts with adequate blinding of both patients and personnel and clear presentation of their methods 
of blinding. However, many studies were subject to a high risk of bias due to small cohort size or insufficient 
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blinding of patients or personnel. Many papers did not describe their methodology of randomisation or 
suffered from attrition (e.g. due to withdrawal from the study or death) resulting in incomplete data capture. 
Selective outcome reporting was seen in three studies and several studies did not present raw data or 
average values of outcome measures. 
 
Neuromuscular electrical stimulation 
Eight studies investigated the efficacy of NMES in addition to usual care [20-24,27-29]. Three of these 
studies assessed both muscle mass/size and muscle function as outcomes [21,22,28], one study assessed 
muscle function alone and 4 studies assessed muscle mass/size alone [20,23-27,29,30].  
 
Of the 3 studies evaluating both muscle mass/size and function, Fischer et al. [22] observed a faster rate of 
improvement of quadriceps muscle strength as measured by mean MRC score during ICU stay in patients 
treated with NMES, however there were no differences in mean MRC score, quadriceps muscle layer 
thickness (MLT), HGS or functional outcomes at hospital discharge. Falavigna et al. [21] found an increased 
range of movement of active dorsiflexion following NMES treatment, however there were no differences in 
leg or thigh circumference or MRC score. Rodriguez et al. [28] found greater preservation of muscle strength 
as measured by MRC score following NMES treatment, however there were no differences in leg or arm 
circumference or bicep thickness.  
 
In the largest of 5 studies evaluating either muscle mass/size or muscle function, Routsi et al. [29] 
demonstrated greater preservation of muscle strength as measured by MRC score (median [range]: 58 
points [33-60 points] vs. 52 points [2-60 points], p=0.04), a shorter duration of weaning from mechanical 
ventilation (median [range]: 1 day [0-16 days] vs. 4 days [0-44 days], p=0.003) and a shorter time off 
mechanical ventilation (median [range]: 4 days [0-16 days] vs. 6 days [0-41 days], p=0.003) in patients 
treated with NMES. However, there were no differences in ICU length of stay (ICU LOS) or total number of 
days on mechanical ventilation. Gerovasili et al. [23] found treatment with NMES lead to a greater 
preservation of quadriceps muscle cross sectional diameter as measured by ultrasound. Similarly, Dirks et 
al. [20] observed greater preservation of quadriceps muscle fibre cross sectional area with NMES treatment. 
However, Poulsen et al. [27] observed no difference in quadriceps muscle volume with NMES treatment  and 
Gruther et al. [24] demonstrated no difference in quadriceps MLT in an acute ICU group (admission <7days), 
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however  they did find greater preservation of quadriceps MLT in the long-term ICU group (admission 
>14days). 
  
Exercise-based interventions 
Seven studies investigated the efficacy of exercise-based interventions in addition to usual care [31-34,36-
38]. None of these studies assessed muscle mass/size as an outcome. The comparator in these studies was 
usual care. Conolly et al. [32] found that an enhanced rehabilitation programme had no effect on 6MWT or 
functional outcomes compared to usual care. Similarly, Denehy et al. [33] found there were no between 
group differences in 6MWT, timed up-and-go test (TUAG) or health related quality of life (HRQoL) at 12 
months post-ICU discharge following a phased rehabilitation programme. Conversely, Burtin et al. [31] found 
that, compared to usual care, patients treated with daily cycle ergometer sessions until ICU discharge had 
greater 6MWT (median [range]: 196m [126-329m] vs.143m [37–226m], p<0.05), improved self-reported 
physical performance (median [range]: 21 points [18–23 points] vs. 15 points [14–23 points], p<0.01) and 
greater improvement in quadriceps force at hospital discharge. However, in this trial there were no 
differences in HGS, duration of weaning from mechanical ventilation, ICU LOS, hospital LOS or 1-year 
mortality.  
 
Yosef-Brauner et al. [38] found that twice daily intensive physical therapy until discharge resulted in a faster 
initial rate of improvement in MRC score and a shorter ICU LOS however the intervention had no effect on 
MRC score improvement or HGS at ICU discharge or duration of mechanical ventilation. In patients treated 
with early, daily physical and occupational therapy sessions, compared to usual care, Schweickert et al. [37] 
observed a greater return to independent functional status (number [%]: 29 [59%] vs. 19 [35%], p=0·02), 
greater maximum walking distance at hospital discharge (median [range]: 33·4m [0–91·4m] vs. 0m [0–
30·4m], p=0·004) and a greater number of ventilator-free days (median [range]: 23·5 days [7·4–25·6 days] 
vs. 21·1 days [0·0–23·8 days], p=0·05). The authors found no differences in MRC score, HGS, ICU LOS, 
hospital LOS or hospital mortality.  
 
Morris et al. [36] found that a programme of standardised rehabilitation therapy sessions three times per day 
had no effect on short physical performance battery (SPPB) score, HGS, hospital LOS, ventilator-free days, 
self-reported physical performance, HRQoL or functional outcomes measured at hospital discharge.  
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Hodgson et al. [34] found that early, goal-directed mobilisation resulted in higher ICU mobility scale score 
compared to usual care however there were no differences in strength or functional outcomes at ICU 
discharge, duration of mechanical ventilation, ventilator-free days, in-hospital mortality, ICU LOS or hospital 
LOS. 
 
Nutrition-based intervention 
Three studies evaluated nutrition-based interventions consisting of early parenteral nutrition or immediate 
postoperative enteral feeding. Watters et al. [41] found that immediate post-op enteral feeding continued for 
6 days, compared to usual care (enteral feeding no sooner than day 6 post-op) had no effect on HGS 
measured 6 days post-op. There were also no differences in ICU LOS, hospital LOS or post-op maximal 
inspiratory capacity between treatment groups however there was greater impairment of post-op forced 
expiratory volume in 1 second and forced vital capacity in the immediate post-op enteral feeding group. 
Caesar et al. [39] found that early parenteral nutrition (starting ≤48hrs after ICU admission) continued for 9 
days compared to late parenteral nutrition (started ≥8 days after ICU admission) had no effect on femoral 
muscle volume, ICU LOS or 90-day mortality. Doig et al. [40] found that early parenteral nutrition (starting 
day 1 of ICU admission) continued until ICU discharge compared with usual care resulted in a shorter 
duration of invasive mechanical ventilation (number of days, adjusted for duration of ICU stay: 7.26 vs. 7.73 
days per 10 patient x ICU days, p=0.01) and reduced self-reported muscle wasting and fat loss. However, 
the authors observed no difference in mid-arm muscle circumference, 60-day mortality, ICU LOS, hospital 
LOS or hospital mortality between groups. 
 
Combined interventions 
Four studies evaluated a combination of two interventions for preservation of muscle mass/size or muscle 
function [25,26,30,35]. Kayambu et al. [25] evaluated early, targeted physical rehabilitation and/or NMES 
continued until ICU discharge, compared with usual care. The authors observed an improvement in HRQoL 
in the domains of ‘physical function’ (mean score ±SD: 81.8 ±22.2 vs. 60.0 ±29.4, p=0.04) and ‘physical role’ 
(mean score ±SD: 61.4 ±43.8 vs. 17.1 ±34.4, p=0.005) measured at 6 months post-ICU discharge in the 
treatment group. However, there were no differences in acute care index of function (ACIF), physical function 
ICU test (PFIT), fat-free mass or MRC score at ICU discharge. Furthermore, there were no differences in 
duration of mechanical ventilation, ICU LOS or ICU readmission rate.  
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Jones et al. [35] evaluated a supervised physiotherapy and exercise programme combined with glutamine 
and essential amino acid supplementation twice daily for 3 months . The authors observed a greater 
improvement in 6MWT at 3 months in the exercise plus nutrition intervention group. However, they observed 
a shorter ICU LOS in the exercise plus placebo group. There was no difference in duration of mechanical 
ventilation between groups. Patsaki et al. [26] evaluated daily NMES combined with a targeted physical 
rehabilitation programme until hospital discharge compared with sham NMES and usual care. The authors 
found no differences in MRC score, HGS, Functional Independence Measure or hospital LOS between 
groups. Finally, in a small trial, Zanotti et al. [30] found that NMES combined with active limb mobilisation 5 
days/week for 28 days resulted in greater improvement in muscle strength score compared with usual care. 
Discussion: 
To our knowledge, this is the first systematic review of interventions for the management and prevention of 
sarcopenia in critically ill patients. In total, we identified 22 RCTs which evaluated the impact of an 
intervention on at least one marker of sarcopenia in critically ill patients. We categorised interventions into 4 
groups: NMES, exercise-based, nutritional and combined interventions. Despite several studies showing 
promising results, the efficacy of interventions for the preservation of muscle mass/size and muscle function 
was variable. NMES represents an appealing intervention to utilise in patients unable to engage in physical 
therapies due to its ability to be performed at the bedside without any need for patient interaction.  However, 
this systematic review suggests more evidence is needed before NMES can be integrated into routine 
clinical practice. Similarly, exercise-based interventions showed variable results and require further 
evaluation.  
 
Neuromuscular electrical stimulation 
Overall, the impact of NMES on sarcopenia markers was inconsistent.  NMES may potentially improve 
muscle strength and preserve muscle mass in critically ill patients. It is important to note however, that 
protocols of NMES administration varied significantly between studies. Protocols consisted of daily or twice-
daily NMES sessions of varying duration (typically <60 minutes), applied to different muscles, started at 
different times during admission and continued for different lengths of time. Furthermore, comparators 
included a mixture of other patients receiving sham treatment/usual care or the intervention patient receiving 
NMES to one leg only, with their contralateral leg as the comparator.  
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Measurement of muscle mass/size was not consistent across studies. Some studies used indirect measures 
(leg and arm circumference) while others used ultrasonography and CT imaging techniques to more 
accurately determine muscle mass/size. Whilst these studies were limited by small numbers there was a 
suggestion that any benefit with NMES probably occurs in patients whose ICU stay is longer, as 
demonstrated by Gruther et al. [24]. This would be consistent with the mechanism by which muscle wasting 
accrues in critical illness. Prolonged bed-rest, inactivity and systemic inflammation are thought to play key 
roles in the development of sarcopenia [2]. Patients with prolonged critical illness and a longer duration of 
admission are therefore more at risk of developing sarcopenia and may benefit from interventions such as 
NMES. The benefit of NMES in the acute phase of critical illness is less clear.  
 
Several studies appeared to show a modest effect of NMES on muscle function. Fischer et al. [22] observed 
a faster initial rate of improvement of quadriceps muscle strength in patients treated with NMES, however 
this effect did not translate into improved quadriceps muscle strength at discharge, nor were there any 
differences in HGS or functional outcomes. Conversely, both Rodriguez et al. [28] and Routsi et al. [29] 
found greater preservation of muscle strength as measured by MRC score in NMES treated patients. The 
effects of NMES on muscle strength seen in these trials might be expected to translate into a shorter 
duration of weaning from mechanical ventilation or reduced disability at hospital discharge, however the 
evidence for this was limited and definitive trials might require powering against such ‘harder’ clinical 
outcomes. 
 
Optimal timing of when to initiate treatment with NMES, frequency of sessions and for how long NMES 
should be continued both during and post-critical care admission requires further research. Similarly, 
protocol standardisation is required regarding choice of target muscles, stimulation intensity, timing and 
duration of individual NMES sessions. Finally, the effect of NMES on meaningful patient centred outcomes 
such as HRQoL and functional outcomes was lacking in these trials and requires further investigation. 
 
Exercise-based interventions 
The impact of exercise-based interventions on muscle function varied, with studies showing conflicting 
results. The exercise protocols used in these trials also varied in timing, frequency and content.  Again, small 
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numbers limit the breadth of conclusions which can be drawn but the available evidence suggests that daily 
therapy is required, since two studies (n=194 patients in total) using this frequency of treatment 
demonstrated improvements in walking distance at hospital discharge [31,37]. Furthermore, 6MWT is a 
validated measure of exercise capacity and may represent a more clinically useful marker of muscle function 
and of cardiovascular fitness than simple measures of muscle strength such as MRC score and HGS. 6MWT 
may therefore be a more clinically relevant marker of response to exercise-based interventions in future 
studies.  
 
Exercise-based interventions had little impact on secondary clinical outcomes. Most studies found no effect 
of exercise-based interventions on ICU LOS, hospital LOS, ventilator-free days or mortality [31,34,36-38]. 
This suggests that future work on exercise-based interventions should focus on intensive treatment in 
appropriately selected patients. Ongoing trials, such as the evaluation of in-bed cycling sessions in addition 
to usual care [42], will provide important new information about the efficacy of exercise-based interventions 
on sarcopenia markers in critically ill patients 
 
Nutrition-based and combined interventions 
Few studies evaluated the impact of nutrition-based interventions on muscle mass/size and function.  
Early enteral and parenteral nutrition had no significant effects on objective measures relevant to sarcopenia 
in these studies [39-41]. In the largest RCT, Doig et al. [40] found that early parenteral nutrition resulted in a 
shorter duration of mechanical ventilation. However, since the authors observed no difference in mid-arm 
muscle circumference, and the only other measure of muscle wasting was self-reported (and thus potentially 
inaccurate), whether this was due to amelioration of sarcopenia or some other mechanism is far from clear.  
 
Combination interventions also showed varied results. Two of three studies combining NMES and 
conventional exercise appeared to show no effect on muscle strength [25,26]. The single study that showed 
benefit must be viewed cautiously due to its small size [30]. In a trial of supervised physiotherapy and 
exercise combined with glutamine and essential amino acid supplementation, Jones et al. [35] observed a 
greater improvement in 6MWT at 3 months post-ICU discharge in the dual intervention group. This study 
suggests that the greatest benefit from combined nutrition and exercise-based interventions may be seen in 
older patients with prolonged ICU admission. In addition, the benefit appears cumulative over time and future 
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trials may wish to investigate the impact of interventions continued for longer periods of time both as an 
inpatient and an outpatient. Finally, none of the combined intervention trials observed any differences in 
secondary clinical outcomes including hospital LOS or duration of mechanical ventilation.   
 
Management and prevention of sarcopenia in non-critically ill patients 
Interventions for the management and prevention of sarcopenia in elderly patients without critical illness 
have been extensively studied; interventions including NMES, exercise-based, nutrition-based and 
multimodal approaches have all previously shown promise in non-critically ill older adults [43, 44, 45]. 
Studies included in this systematic review comprised a heterogenous population of critically ill patients with a 
variety of co-morbidities. The aetiological differences in these patients and the heterogeneity of mechanisms 
underlying sarcopenia may partly explain some of the differences observed in the efficacy of the 
interventions on measures of muscle mass and function. Further research examining specific sub-
populations of critically ill patients with, for example, respiratory failure related to underlying chronic 
obstructive pulmonary disease, may provide valuable information regarding the efficacy of interventions in 
specific patient groups [46]. 
 
Limitations 
Studies included in this review did not explicitly report metrics on sarcopenia diagnosis /severity, rather they 
reported measures of sarcopenia: muscle mass/size and muscle function. Only 4 studies evaluated both 
components of sarcopenia, making it difficult to draw definitive conclusions about the impact of the 
interventions on sarcopenia. Due to heterogeneity of study design, interventions used, and outcomes 
measured, meta-analysis was not possible. Furthermore, although all patients included in this study met our 
inclusion criteria of being critically ill, this systematic review represents a heterogeneous cohort. There was a 
high risk of bias in many of the studies, particularly in the domains of performance bias, due to a lack of 
blinding of patients and personnel to interventions, and attrition bias due to high numbers of patient 
withdrawal resulting in small study size and a lack of statistical power.   
 
Recommendations for further research 
Larger, high quality RCTs are required which evaluate the impact of interventions on accepted measures of 
sarcopenia. Our review suggests that the most promising interventions are NMES and daily exercise, which 
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might be used in combination, or in different patient groups. Since benefits may accrue more in older 
patients with prolonged ICU stay, this would be a priority group in whom to obtain specific data. Future 
studies should also be wary of the risk of attrition, as seen in many of the studies included in this review, 
which may affect statistical power. To facilitate data comparison and quantitative synthesis of findings, 
mechanistic studies should seek to standardise techniques for the measurement of muscle mass/size and 
muscle function in critical care, or to enhance their clinical relevance by use of a functional outcome, such as 
duration of ventilation, or walk distance at discharge from hospital as their primary outcome. The 
methodological challenges of measuring muscle mass and function remain an important area for future 
research in both patients with critical illness and in older adults with aging-related sarcopenia [47]. 
 
Conclusions 
NMES and exercise-based interventions may help preserve muscle mass and function in critically ill patients. 
The lack of high quality methodology and small cohort size in many of the studies limits the confidence in 
these findings. Standardisation of sarcopenia outcome measurement in critical care is needed to ensure 
validity and reproducibility and to facilitate quantitative synthesis of study findings. Further, large, high quality 
RCTs are required to identify the most effective interventions for the management and prevention of 
sarcopenia in critically ill patients. 
 
 
 
 
 
References 
[1] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European 
consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older 
People. Age Ageing 2010 Jul;39(4):412-423. 
[2] Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth 2016 
Oct;30(5):884-890. 
[3] Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. Geriatr Gerontol Int 2012 
Jul;12(3):388-396. 
[4] Peterson SJ, Braunschweig CA. Prevalence of Sarcopenia and Associated Outcomes in the Clinical 
Setting. Nutr Clin Pract 2016 Feb;31(1):40-48. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
[5] Sousa AS, Guerra RS, Fonseca I, Pichel F, Amaral TF. Sarcopenia among hospitalized patients - A 
cross-sectional study. Clin Nutr 2015 Dec;34(6):1239-1244. 
[6] Sheean PM, Peterson SJ, Gomez Perez S, Troy KL, Patel A, Sclamberg JS, et al. The prevalence of 
sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography 
and subjective global assessment. JPEN J Parenter Enteral Nutr 2014 Sep;38(7):873-879. 
[7] Weijs PJ, Looijaard WG, Dekker IM, Stapel SN, Girbes AR, Oudemans-van Straaten HM, et al. Low 
skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill pat ients. Crit Care 
2014 Jan 13;18(2):R12. 
[8] Gariballa S, Alessa A. Sarcopenia: prevalence and prognostic significance in hospitalized patients. Clin 
Nutr 2013 Oct;32(5):772-776. 
[9] Ji Y, Cheng B, Xu Z, Ye H, Lu W, Luo X, et al. Impact of sarcopenic obesity on 30-day mortality in 
critically ill patients with intra-abdominal sepsis. J Crit Care 2018 Aug;46:50-54. 
[10] Ju S, Choi SM, Park YS, Lee CH, Lee SM, Yoo CG, et al. Rapid Muscle Loss Negatively Impacts 
Survival in Critically Ill Patients With Cirrhosis. J Intensive Care Med 2018 Jan 1:885066618775706. 
[11] Schefold JC, Bierbrauer J, Weber-Carstens S. Intensive care unit-acquired weakness (ICUAW) and 
muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Musc le 
2010 Dec;1(2):147-157. 
[12] Toptas M, Yalcin M, Akkoc I, Demir E, Metin C, Savas Y, et al. The Relation between Sarcopenia and 
Mortality in Patients at Intensive Care Unit. Biomed Res Int 2018 Feb 12;2018:5263208.  
[13] Yeh DD, Ortiz-Reyes LA, Quraishi SA, Chokengarmwong N, Avery L, Kaafarani HMA, et al. Early 
nutritional inadequacy is associated with psoas muscle deterioration and worse clinical outcomes in critically 
ill surgical patients. J Crit Care 2018 Jun;45:7-13. 
[14] Boutin RD, Yao L, Canter RJ, Lenchik L. Sarcopenia: Current Concepts and Imaging Implications. AJR 
Am J Roentgenol 2015 Sep;205(3):255. 
[15] Rubbieri G, Mossello E, Di Bari M. Techniques for the diagnosis of sarcopenia. Clin Cases Miner Bone 
Metab 2014 Sep;11(3):181-184. 
[16] Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al. Age-associated changes in 
skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985) 
2003 Nov;95(5):1851-1860. 
[17] Cawthon PM. Assessment of Lean Mass and Physical Performance in Sarcopenia. J Clin Densitom 
2015;18(4):467-471. 
[18] Hodgson CL, Capell E, Tipping CJ. Early Mobilization of Patients in Intensive Care: Organization, 
Communication and Safety Factors that Influence Translation into Clinical Practice. Crit Care 2018 Mar 
20;22(1):9. 
[19] Parry SM, Berney S, Granger CL, Koopman R, El-Ansary D, Denehy L. Electrical muscle stimulation in 
the intensive care setting: a systematic review. Crit Care Med 2013 Oct;41(10):2406-2418. 
[20] Dirks ML, Hansen D, Van Assche A, Dendale P, Van Loon LJ. Neuromuscular electrical stimulation 
prevents muscle wasting in critically ill comatose patients. Clin Sci (Lond) 2015 Mar;128(6):357-365. 
[21] Falavigna LF, Silva MG, Freitas AL, Silva PF, Paiva Junior MD, de Castro CM, et al. Effects of electrical 
muscle stimulation early in the quadriceps and tibialis anterior muscle of critically ill patients. Physiother 
Theory Pract 2014 May;30(4):223-228. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
[22] Fischer A, Spiegl M, Altmann K, Winkler A, Salamon A, Themessl-Huber M, et al. Muscle mass, strength 
and functional outcomes in critically ill patients after cardiothoracic surgery: does neuromuscular electrical 
stimulation help? The Catastim 2 randomized controlled trial. Crit Care 2016 Jan 29;20:3.  
[23] Gerovasili V, Stefanidis K, Vitzilaios K, Karatzanos E, Politis P, Koroneos A, et al. Electrical muscle 
stimulation preserves the muscle mass of critically ill patients: a randomized study. Crit Care 
2009;13(5):R161. 
[24] Gruther W, Kainberger F, Fialka-Moser V, Paternostro-Sluga T, Quittan M, Spiss C, et al. Effects of 
neuromuscular electrical stimulation on muscle layer thickness of knee extensor muscles in intensive care 
unit patients: a pilot study. J Rehabil Med 2010 Jun;42(6):593-597. 
[25] Kayambu G, Boots R, Paratz J. Early physical rehabilitation in intensive care patients with sepsis 
syndromes: a pilot randomised controlled trial. Intensive Care Med 2015 May;41(5):865-874. 
[26] Patsaki I, Gerovasili V, Sidiras G, Karatzanos E, Mitsiou G, Papadopoulos E, et al. Effect of 
neuromuscular stimulation and individualized rehabilitation on muscle strength in Intensive Care Unit 
survivors: A randomized trial. J Crit Care 2017 Aug;40:76-82. 
[27] Poulsen JB, Moller K, Jensen CV, Weisdorf S, Kehlet H, Perner A. Effect of transcutaneous electrical 
muscle stimulation on muscle volume in patients with septic shock. Crit Care Med 2011 Mar;39(3):456-461. 
[28] Rodriguez PO, Setten M, Maskin LP, Bonelli I, Vidomlansky SR, Attie S, et al. Muscle weakness in 
septic patients requiring mechanical ventilation: protective effect of transcutaneous neuromuscular electrical 
stimulation. J Crit Care 2012 Jun;27(3):319.e8. 
[29] Routsi C, Gerovasili V, Vasileiadis I, Karatzanos E, Pitsolis T, Tripodaki E, et al. Electrical muscle 
stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. Crit Care 
2010;14(2):R74. 
[30] Zanotti E, Felicetti G, Maini M, Fracchia C. Peripheral muscle strength training in bed-bound patients 
with COPD receiving mechanical ventilation: effect of electrical stimulation. Chest 2003 Jul;124(1):292-296. 
[31] Burtin C, Clerckx B, Robbeets C, Ferdinande P, Langer D, Troosters T, et al. Early exercise in critically 
ill patients enhances short-term functional recovery. Crit Care Med 2009 Sep;37(9):2499-2505. 
[32] Connolly B, Thompson A, Douiri A, Moxham J, Hart N. Exercise-based rehabilitation after hospital 
discharge for survivors of critical illness with intensive care unit-acquired weakness: A pilot feasibility trial. J 
Crit Care 2015 Jun;30(3):589-598. 
[33] Denehy L, Skinner EH, Edbrooke L, Haines K, Warrillow S, Hawthorne G, et al. Exercise rehabilitation 
for patients with critical illness: a randomized controlled trial with 12 months of follow-up. Crit Care 2013 Jul 
24;17(4):R156. 
[34] Hodgson CL, Bailey M, Bellomo R, Berney S, Buhr H, Denehy L, et al. A Binational Multicenter Pilot 
Feasibility Randomized Controlled Trial of Early Goal-Directed Mobilization in the ICU. Crit Care Med 2016 
Jun;44(6):1145-1152. 
[35] Jones C, Eddleston J, McCairn A, Dowling S, McWilliams D, Coughlan E, et al. Improving rehabilitation 
after critical illness through outpatient physiotherapy classes and essential amino acid supplement: A 
randomized controlled trial. J Crit Care 2015 Oct;30(5):901-907. 
[36] Morris PE, Berry MJ, Files DC, Thompson JC, Hauser J, Flores L, et al. Standardized Rehabilitation and 
Hospital Length of Stay Among Patients With Acute Respiratory Failure: A Randomized Clinical Trial. JAMA 
2016 Jun 28;315(24):2694-2702. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
[37] Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and 
occupational therapy in mechanically ventilated, critically ill patients: a randomised c ontrolled trial. Lancet 
2009 May 30;373(9678):1874-1882. 
[38] Yosef-Brauner O, Adi N, Ben Shahar T, Yehezkel E, Carmeli E. Effect of physical therapy on muscle 
strength, respiratory muscles and functional parameters in patients with intensive care unit -acquired 
weakness. Clin Respir J 2015 Jan;9(1):1-6. 
[39] Casaer MP, Langouche L, Coudyzer W, Vanbeckevoort D, De Dobbelaer B, Guiza FG, et al. Impact of 
early parenteral nutrition on muscle and adipose tissue compartments during critical illness. Crit Care Med 
2013 Oct;41(10):2298-2309. 
[40] Doig GS, Simpson F, Sweetman EA, Finfer SR, Cooper DJ, Heighes PT, et al. Early parenteral nutrition 
in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized 
controlled trial. JAMA 2013 May 22;309(20):2130-2138. 
[41] Watters JM, Kirkpatrick SM, Norris SB, Shamji FM, Wells GA. Immediate postoperative enteral feeding 
results in impaired respiratory mechanics and decreased mobility. Ann Surg 1997 Sep;226(3):80.  
[42] Nickels MR, Aitken LM, Walsham J, Barnett AG, McPhail SM. Critical Care Cycling Study (CYCLIST) 
trial protocol: a randomised controlled trial of usual care plus additional in-bed cycling sessions versus usual 
care in the critically ill. BMJ Open 2017 Oct 22;7(10):017393. 
[43] Yoshimura Y, Wakabayashi H, Yamada M, Kim H, Harada A, Arai H.  Interventions for Treating 
Sarcopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. J Am Med Dir 
Assoc. 2017 Jun 1;18(6):553.e1-553.e16. 
[44] O'Connor D, Brennan L, Caulfield B. The use of neuromuscular electrical stimulation (NMES) for 
managing the complications of ageing related to reduced exercise participation.  Maturitas. 2018 Jul;113:13-
20. 
[45] Lozano-Montoya I, Correa-Pérez A, Abraha I, Soiza RL, Cherubini A, O'Mahony D, et al. 
Nonpharmacological interventions to treat physical frailty and sarcopenia in older patients: a systematic 
overview - the SENATOR Project ONTOP Series. Clin Interv Aging. 2017 Apr 24;12:721-740. 
[46] Maddocks M, Nolan CM, Man WD, Polkey MI, Hart N, Gao W, et al. Neuromuscular electrical 
stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-
controlled trial. Lancet Respir Med. 2016 Jan;4(1):27-36. 
[47] Correa-de-Araujo R, Harris-Love MO, Miljkovic I, Fragala MS, Anthony BW, TM Manini. The Need for 
Standardized Assessment of Muscle Quality in Skeletal Muscle Function Deficit and Other Aging-Related 
Muscle Dysfunctions: A Symposium Report. Front Physiol. 2017;8:87. 
 Table 1. Summary of randomised controlled trials. 
 
Source No of 
patient
s  
Age (years)  Intervention Comparat
or 
Outcomes – 
Muscle 
Mass 
Outcomes 
– Muscle 
Function 
Outcomes - 
Other 
Main 
findings 
Fischer  
2016 
54 C: 
69.7 
(±13.1
) 
 
I: 63.3 
(±15.5
) 
NMES 
- Tw ice daily 
30-min 
sessions on 
quadriceps 
(bilateral) 
started day 1 
post-op, 
continued 
until 
Sham 
NMES 
 
Quadriceps 
MLT 
 
 
MRC score; 
HGS 
Functional 
Independen
ce Measure; 
TUAG 
Faster rate 
of 
improvemen
t of MRC 
score during 
ICU stay in 
intervention 
group. No 
signif icant 
differences 
in 
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discharge or 
max 14 days 
quadriceps 
MLT, mean 
MRC score 
or HGS at 
hospital 
discharge. 
No 
signif icant 
differences 
in functional 
outcomes. 
 
Falavigna 
2014 
 
25 34.0 (±17.3) 
 
NMES 
- Daily 20-min 
sessions on 
quadriceps 
and tibialis 
anterior 
(unilateral) 
until a force of 
4 on the MRC 
scale 
obtained 
Contralater
al leg - 
usual care 
Leg and 
thigh 
circumferenc
e 
MRC score; 
ankle joint 
movement 
 Increased 
range of 
movement 
of active 
dorsif lexion 
in 
intervention 
leg. No 
signif icant 
differences 
in leg or 
thigh 
circumferenc
e or MRC 
score. 
 
 
Rodriguez 
2012 
 
16 72 [63-80] NMES 
- Tw ice daily 
30-min 
sessions on 
biceps brachii 
and vastus 
medialis 
(unilateral) 
until 
successful 
extubation 
Contralater
al leg - 
usual care 
Leg and arm 
circumferenc
e; biceps 
thickness 
MRC score  Greater 
preservation 
of muscle 
strength as 
measured 
by MRC 
score in 
intervention 
leg. No 
signif icant 
differences 
in leg or arm 
circumferenc
e or bicep 
thickness. 
 
Routsi  
2010 
 
140 C: 58 
(±18) 
 
I: 61 
(±19) 
NMES 
- Daily 55-min 
sessions on 
quadriceps 
and peroneus 
longus 
(bilateral) 
started on day 
2 post-
admission, 
continued 
until 
discharge 
Usual care  
 
MRC score 
 
ICU LOS; 
MV days; 
duration of 
w eaning 
period from 
MV; days 
off ventilator 
Greater 
preservation 
of muscle 
strength as 
measured 
by MRC 
score in 
intervention 
group. 
Shorter 
duration of 
w eaning 
period from 
MV and 
days off 
ventilator in 
intervention 
group. No 
signif icant 
differences 
in ICU LOS 
or MV days. 
Dirks  
2015 
9 63 (±6) NMES 
- Tw ice daily 
40-min 
sessions on 
quadriceps 
(unilateral) 
until aw oken 
Contralater
al leg – 
sham 
NMES 
Leg 
circumferenc
e; 
quadriceps 
muscle f ibre 
CSA 
  Greater 
preservation 
of 
quadriceps 
muscle f ibre 
CSA in 
intervention 
leg. 
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from sedation 
Gerovasili 
2009  
49 C:56 
(±19) 
 
 
I: 59 
(±23) 
NMES 
- Daily 55-min 
sessions on 
quadriceps 
and peroneus 
longus 
(bilateral) 
started on day 
2 post-
admission, 
continued 
until day 9 
Usual care Quadriceps 
CSD  
 
 
 
  Greater 
preservation 
of 
quadriceps 
CSD in 
intervention 
group. 
 
 
Poulsen 
2011 
8 67 [64-72] NMES 
- Daily 60-min 
sessions on 
quadriceps 
(unilateral) for 
7 days 
Contralater
al leg - 
usual care 
Quadriceps 
muscle 
volume 
  No 
signif icant 
differences 
in 
quadriceps 
muscle 
volume. 
Gruther  
2010 
46 C-A: 
48(±1
2) 
 
C-L: 
64(±8) 
I-A: 
52(±1
0) 
 
I-L: 
61(±1
0) 
NMES 
- Daily 30-min 
sessions in 
w eek one 
follow ed by 
daily 60-min 
sessions on 
quadriceps 
(bilateral) 
treatment 5 
days a w eek 
for a total of 4 
w eeks 
Sham Quadriceps 
MLT 
  Greater 
preservation 
of 
quadriceps 
MLT in long-
term patient 
intervention 
group. No 
signif icant 
differences 
in 
quadriceps 
MLT in 
acute patient 
group. 
Connolly 
2015 
20 C: 
68.5 
[64.3-
79] 
I: 63 
[46.8-
71.8] 
Exercise  
- 
Rehabilitation 
programme: 2 
x 40-min 
sessions/wee
k for 3 months 
Usual care  6MWT; 
incremental 
shuttle w alk 
test 
SF-36 
 
 
No 
signif icant 
differences 
in primary or 
secondary 
outcomes. 
 
 
Denehy 
2013 
150 C: 
60.1 
(±15.8
) 
I: 61.4 
(±15.9
) 
Exercise 
- Phased 
rehabilitation 
programme: 2 
x 15-min 
sessions/day 
on ICU, 2 x 
30-min 
sessions/day 
on w ard 
follow ed by 2 
x 60-min 
sessions/wee
k as 
outpatient for 
further 8 
w eeks 
Usual care  
 
6MWT 
 
TUAG; 
HRQoL 
No 
signif icant 
differences 
in 6MWT, 
TUAG or 
HRQoL at 
12 months 
post-ICU 
discharge.  
 
 
Burtin  
2009 
90 
 
C: 57 
(±17) 
I: 56 
(±16) 
Exercise 
- Daily 20-min 
bedside cycle 
ergometer 
sessions 
starting no 
earlier than 
day 5 of 
Usual care  
 
 
6MWT; 
HGS; 
quadriceps 
force 
 
SF-36 PF; 
w eaning 
time, ICU 
LOS; 
hospital 
LOS; 1-yr 
mortality 
 
Greater 
6MWT, SF-
36 PF and 
improvemen
t in 
quadriceps 
force at 
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admission, 5 
times/w eek 
until ICU 
discharge 
 hospital 
discharge in 
the 
intervention 
group. No 
signif icant 
differences 
in HGS, 
w eaning 
time, ICU 
LOS, 
hospital LOS 
or 1-yr 
mortality. 
 
Yosef-
Brauner 
2013 
 
18 C: 
61.5 
(±12) 
I: 51.6 
(±18) 
Exercise 
- Tw ice daily 
intensive 
physical 
therapy until 
discharge 
Usual care  
 
 
MRC score; 
HGS 
 
ICU LOS; 
MV days 
Faster initial 
rate of 
improvemen
t in MRC 
score in 
intervention 
group. 
Shorter ICU 
LOS in 
intervention 
group. No 
signif icant 
differences 
in MRC 
score 
improvemen
t or HGS at 
ICU 
discharge. 
No 
signif icant 
dif ference in 
MV days. 
Schw eick
ert 2009 
104  
 
 
C: 
54·4 
(46·5–
66·4) 
I: 57·7 
(36·3–
69·1) 
Exercise 
- Early, daily 
physical and 
occupational 
therapy 
sessions until 
functional 
baseline 
reached or 
discharged 
from hospital 
Usual care  Functional 
Independen
ce Measure; 
MRC score; 
HGS; 
maximum 
w alking 
distance 
Ventilator-
free days; 
ICU LOS; 
hospital 
LOS; 
hospital 
mortality 
 
 
Increased 
return to 
independent 
functional 
status, 
maximum 
w alking 
distance and 
ventilator-
free days in 
intervention 
group. No 
signif icant 
differences 
in MRC 
score, HGS, 
ICU LOS, 
hospital LOS 
or hospital 
mortality. 
Morris  
2016 
300 
 
 
C: 58 
(±14) 
I: 55 
(±17) 
Exercise 
- 
Standardised 
rehabilitation 
therapy: 
sessions 
three 
times/day 
Usual care  
 
SPPB; HGS 
 
Hospital 
LOS; 
ventilator 
free days; 
SF-36 PF; 
Functional 
Performanc
e Inventory; 
No 
signif icant 
differences 
in any of the 
outcomes 
measured at 
hospital 
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including 
passive range 
of motion, 
physical 
therapy, and 
progressive 
resistance 
exercises 
HRQoL discharge. 
Hodgson 
2016 
50 C: 53 
(15) 
I: 64 
(12) 
Exercise 
- Early goal-
directed 
mobilization: 
daily 30-60-
min sessions 
comprising 
active 
functional 
activities 
Usual care  ICU mobility 
scale; PFIT; 
Functional 
Status 
Score in 
ICU test; 
MRC score 
In-hospital 
mortality; 
MV days; 
ICU LOS; 
hospital 
LOS; 
ventilator 
free days 
Higher 
maximum 
ICU mobility 
scale score 
in 
intervention 
group. No 
signif icant 
differences 
in strength 
or functional 
outcomes at 
ICU 
discharge, 
MV days, 
ventilator 
free days, 
in-hospital 
mortality, 
ICU LOS or 
hospital LOS 
Watters 
1997 
31  
 
 
C: 61 
(±12) 
I: 64 
(±11) 
Nutrition 
- Immediate 
post-op 
enteral 
feeding 
20mL/hr max 
2500ml/day 
for 6 days 
Usual care 
- Enteral 
feeding no 
sooner 
than day 6 
post-op 
 
 
HGS; FEV1; 
FVC; 
maximal 
inspiratory 
pressure 
 
ICU LOS; 
hospital 
LOS 
No 
signif icant 
difference in 
HGS 6 days 
post-op. No 
signif icant 
differences 
in ICU LOS, 
hospital LOS 
or post-op 
maximal 
inspiratory 
capacity. 
Greater 
impairment 
of post-op 
FEV1 and 
FVC in 
intervention 
group. 
Casaer  
2013 
15 
 
C: 50 
(±16) 
I: 44 
(±14) 
Nutrition 
- Early 
parenteral 
nutrition 
(≤48hrs after 
ICU 
admission) 
daily for 9 
days 
Late 
Parenteral 
nutrition 
(≥8 days 
after ICU 
admission) 
Femoral 
muscle 
volume 
 
 
 ICU LOS; 
90-day 
mortality 
No 
signif icant 
difference in 
femoral 
muscle 
volume. No 
signif icant 
differences 
in ICU LOS 
or 90-day 
mortality. 
 
 
Doig  
2013 
1372 
 
 
C: 
68.6 
(±14.3
) 
I: 68.4 
(±15.1
) 
Nutrition 
- Early 
parenteral 
nutrition 
(starting day 1 
Usual care Mid-arm 
muscle 
circumferenc
e; muscle 
w asting and 
 60-day 
mortality; 
ICU LOS; 
hospital 
LOS; 
Few er MV 
days and 
reduced 
muscle 
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of ICU 
admission) 
until ICU 
discharge 
fat loss 
(subjective) 
 
 
hospital 
mortality; 
MV days 
w asting and 
fat loss 
(subjective) 
in 
intervention 
group. No 
signif icant 
differences 
in mid-arm 
muscle 
circumferenc
e, 60-day 
mortality, 
ICU LOS, 
hospital LOS 
or hospital 
mortality. 
 
Jones  
2015 
 
93 
 
 
C: 60 
(±12) 
 
E: 64 
(±18) 
CP: 
64 
(±13) 
 
EP: 62 
(±14) 
Combined 
- Supervised 
physiotherapy 
and exercise 
programme, 3 
times/w eek as 
IP follow ed by 
w eekly 
sessions as 
OP for 6 
w eeks ± 
glutamine and 
essential 
amino acid 
supplementati
on tw ice daily 
for 3 months 
Usual care 
or placebo 
 
 
6MWT 
 
ICU LOS; 
MV days 
Greater 
improvemen
t in 6MWT at 
3 months in 
the exercise 
+ nutrition 
intervention 
group. 
Shorter ICU 
LOS in the 
exercise + 
placebo 
group. No 
signif icant 
differences 
in MV days. 
Patsaki  
2017 
128 
 
 
C: 53 
(±16) 
I: 53 
(±15) 
Combined 
- Daily 55-min 
NMES 
sessions on 
rectus femoris 
and peroneus 
longus 
(bilateral) + 
targeted 
physical 
rehabilitation 
programme 5 
days/week 
until hospital 
discharge 
Sham 
NMES and 
usual care 
 
 
MRC score; 
HGS 
 
Hospital 
LOS; 
Functional 
Independen
ce Measure 
No 
signif icant 
differences 
in MRC 
score, HGS, 
Functional 
Independen
ce Measure 
or hospital 
LOS. 
 
Zanotti  
2003 
24 
 
 
C:64.5 
(±4) 
I:66.2 
(±8) 
Combined 
- 30-min 
NMES 
sessions on 
quadriceps 
and vastus 
gluteus 5 
days/week for 
28 days + 30-
min active 
limb 
mobilisation 
sessions 5 
days/week for 
28 days 
Usual care  
 
Muscle 
strength 
score 
 
 Greater 
improvemen
t in muscle 
strength 
score in the 
intervention 
group. 
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Kayambu 
2015 
50 
 
 
C: 
65.5 
[37-
85] 
I: 62.5 
[30-
83] 
Combined 
- Early, 
targeted 
physical 
rehabilitation: 
30-min 
sessions 1-2 
times/day 
consisting of 
exercise 
and/or NMES 
to quadriceps, 
tibialis 
anterior and 
brachioradiali
s, continued 
until ICU 
discharge 
 
Usual care Fat-free 
mass 
 
 
ACIF; PFIT; 
MRC score 
ICU LOS; 
ICU 
readmission
; MV days; 
SF-36; 
physical 
functional 
ICU test 
Improvemen
t in HRQoL 
at 6 months 
post-ICU 
discharge in 
‘physical 
function’ and 
‘physical 
role’ in 
intervention 
group. No 
signif icant 
differences 
in ACIF, 
physical 
function ICU 
test, fat-free 
mass or 
MRC score 
at ICU 
discharge. 
No 
signif icant 
differences 
in MV days, 
ICU LOS or 
ICU 
readmission. 
Abbreviations: NMES, neuromuscular electrical stimulation; MLT, muscle layer thickness; HGS, hand grip strength; TUAG, timed up and 
go test; MRC, Medical Research Council muscle strength score; LOS, length of stay; MV, mechanical ventilation; CSA, cross sec tional 
area; CSD, cross sectional diameter; 6MWT, 6 metre w alk test; SF-36, 36-item short form survey; HRQoL, health related quality of life; 
SF-36 PF, physical function component of the 36-Item Short-Form Health Survey; ACIF, acute care index of function; PFIT, Physical 
Function in ICU Test; SPPB, short performance physical battery. 
 
Table 2. Sarcopenia related outcomes used in the randomised controlled trials. 
 
Muscle Mass Muscle Function 
Quadriceps muscle layer thickness (MLT)* MRC score 
Quadriceps muscle cross sectional diameter (CSD)* Hand grip strength (HGS) 
Biceps thickness* 6-minute w alk test (6MWT) 
Quadriceps muscle f ibre cross sectional area (CSA)** Maximum w alking distance 
Quadriceps muscle volume*** Quadriceps force 
Femoral muscle volume*** Ankle joint movement 
Fat-free mass**** Incremental shuttle w alk test 
Mid-arm muscle circumference Muscle strength score 
Leg and arm circumference Short physical performance battery (SPPB) 
Muscle w asting and fat loss score (subjective) Physical function outcome measure (PFIT) 
 Acute care index of function (ACIF) 
 Functional independence measure 
 ICU mobility scale 
 Functional Status Score in ICU test 
*Quadriceps MLT, quadriceps CSD and biceps thickness w ere measured using ultrasonography; **Quadriceps CSA w as measured 
using muscle biopsy; ***Quadriceps muscle volume and femoral muscle volume w ere measured using computed tomography; **** Fat-
free mass w as measured using multi-frequency bioelectrical impedance spectroscopy. 
 
Figure 1. PRISMA flow diagram illustrating study selection.  
Figure 2. Risk of bias summary. 
 
Highlights 
 NMES and exercise-based interventions may preserve muscle mass and function. 
 A lack of consistency is seen in the effects of these interventions.  
 Standardisation of sarcopenia outcome measurement is needed. 
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 Further, large, high quality randomised controlled trials are required. 
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